‘Da Vinci’ monopoly-Robot operation market, Korea to be next challenge
Nam Do Yeong | namdo0@ | 2018-04-04 10:45:06
Korean manufacturing companies are challenging the surgical robot market, which is dominated by foreign products.
According to the medical device industry on April 3, Korean companies such as Future Company, Cirexo, and Koh Young Technology are stepping into the surgical robot market. Mirae Company recently launched the domestic surgical robot `Levoi`, which will be against the US laparoscopic surgical robot `Da Vinci`, which is leading the surgical robot market. Levee, which has been approved by the Food and Drug Administration last year for 10 years, started to develop based on pure domestic technology in 2007, and is challenging the surgical robot market with 42% less operation cost than Da Vinci. Revo Eye is similar to Da Vinci in applications such as cholecystectomy and prostatectomy, but it can drive endoscopes and surgical instruments simultaneously with fewer passages than conventional channels.
CECEXO, which acquired the Robodak orthopedic surgical robot from IBM`s US-based medical device manufacturer in 2007, entered the surgical robot market. The company is currently developing a second-generation orthopedic surgical robot `T Solution One` It sells in the country. CLEXO is pursuing the development of a Korean orthopedic robot separate from the TIME SOLUTION, and has been working with Yonsei Medical Center to develop a spinal surgery robot using the interventional robot platform that was acquired by Hyundai Heavy Industries` medical robot division last year. In addition, the Xeno Guide, a brain surgery robot developed by Kooyoung Technology, a maker of 3D measurement equipment, is licensed to manufacture and sell drugs in December 2016 and is preparing for domestic launch and entry into the US market.
The market for surgical robots is considered to be a field with high entry barriers to new companies as it needs to accumulate long-term clinical experience as well as high technology. However, Da Vinci, a leading manufacturer of surgical robots, has announced an open strategy to open up patents and strengthen cooperation in line with the expiration of their original patents. Opportunities for latecomers to enter the market or to cooperate with the front runners are open.
It is now expected that Korea will be able to develop world-class products if it invests in original technology development because it has strengths in information technology (IT) and medical industry as well as robot industry. Lee Jae-Sun, managing director of Future Company, said, "Medical robots will be developed in various directions by combining with other fields such as using big data and applying artificial intelligence." "To complement the technological development of the domestic medical robots industry and a bipartisan level of support is needed every week."
Surgical robots, on the other hand, are growing as they are used for surgery that requires high-precision and high-tech techniques beyond the limits of human beings, despite expensive equipment and surgery costs.
According to the Korea Food and Drug Administration, the world market for surgical robots is expected to reach KRW 5.2 trillion in 2016, an annual average of 13.2% to reach KRW 9.6 trillion in 2021.
By Nam Do Yeong namdo0@
[ copyright ⓒ The Digitaltimes ]
According to the medical device industry on April 3, Korean companies such as Future Company, Cirexo, and Koh Young Technology are stepping into the surgical robot market. Mirae Company recently launched the domestic surgical robot `Levoi`, which will be against the US laparoscopic surgical robot `Da Vinci`, which is leading the surgical robot market. Levee, which has been approved by the Food and Drug Administration last year for 10 years, started to develop based on pure domestic technology in 2007, and is challenging the surgical robot market with 42% less operation cost than Da Vinci. Revo Eye is similar to Da Vinci in applications such as cholecystectomy and prostatectomy, but it can drive endoscopes and surgical instruments simultaneously with fewer passages than conventional channels.
CECEXO, which acquired the Robodak orthopedic surgical robot from IBM`s US-based medical device manufacturer in 2007, entered the surgical robot market. The company is currently developing a second-generation orthopedic surgical robot `T Solution One` It sells in the country. CLEXO is pursuing the development of a Korean orthopedic robot separate from the TIME SOLUTION, and has been working with Yonsei Medical Center to develop a spinal surgery robot using the interventional robot platform that was acquired by Hyundai Heavy Industries` medical robot division last year. In addition, the Xeno Guide, a brain surgery robot developed by Kooyoung Technology, a maker of 3D measurement equipment, is licensed to manufacture and sell drugs in December 2016 and is preparing for domestic launch and entry into the US market.
The market for surgical robots is considered to be a field with high entry barriers to new companies as it needs to accumulate long-term clinical experience as well as high technology. However, Da Vinci, a leading manufacturer of surgical robots, has announced an open strategy to open up patents and strengthen cooperation in line with the expiration of their original patents. Opportunities for latecomers to enter the market or to cooperate with the front runners are open.
It is now expected that Korea will be able to develop world-class products if it invests in original technology development because it has strengths in information technology (IT) and medical industry as well as robot industry. Lee Jae-Sun, managing director of Future Company, said, "Medical robots will be developed in various directions by combining with other fields such as using big data and applying artificial intelligence." "To complement the technological development of the domestic medical robots industry and a bipartisan level of support is needed every week."
Surgical robots, on the other hand, are growing as they are used for surgery that requires high-precision and high-tech techniques beyond the limits of human beings, despite expensive equipment and surgery costs.
According to the Korea Food and Drug Administration, the world market for surgical robots is expected to reach KRW 5.2 trillion in 2016, an annual average of 13.2% to reach KRW 9.6 trillion in 2021.
By Nam Do Yeong namdo0@